Seedlabs

IL-38 Tumor Immune-Escape Score

A biopsy test that identifies if a tumor is hiding from the immune system to help pick the right therapy.

A pathology test measuring IL-38 expression in tumor biopsies to identify cancers using IL-38 as an immune-evasion mechanism, enabling patient selection for IL-38-blocking immunotherapy trials.

Biochemistry, Genetics and Molecular BiologyInflammasome and immune disorders
Metabolism and Genetic DisordersImmuno-oncology companion diagnostics for IL-38-blocking antibody development

Concept

A standardized immunohistochemistry (IHC) or RNA in-situ hybridization assay performed on routine tumor biopsy sections that quantifies IL-38 expression in the tumor microenvironment. The output is an "IL-38 Immune-Escape Score" that flags tumors actively suppressing anti-cancer immunity through IL-38-mediated immunosuppression. Pharmaceutical companies developing IL-38-blocking antibodies would use this as a companion diagnostic to enroll only IL-38-high patients in clinical trials, and oncologists would eventually use it to identify patients whose "cold" tumors might respond to IL-38 blockade combined with existing checkpoint inhibitors.

Why now

The paper demonstrates that antibody-mediated targeting of IL-38 reactivates immunostimulatory mechanisms and has anticancer effects in preclinical cancer models. This establishes IL-38 as a druggable immune-evasion axis and creates an immediate need for a tissue-based diagnostic to identify which patients' tumors actually express IL-38 at immunosuppressive levels. Because IL-38 blockade is preclinical, the first commercial application is as a translational biomarker for pharma trial enrollment — a lower regulatory bar than a therapeutic, and a proven companion-diagnostic business model.

Written by GLM · 11 Oct 2026

AI assessment

Backed by 1 paper84

A highly focused companion diagnostic for a specific preclinical drug target, leveraging a proven pharma business model with strong technical feasibility.

Evidence strength
4/5
The full text explicitly states that IL-38 antibody-mediated targeting has anticancer effects in preclinical models, directly supporting the need for a biomarker to identify high-expressors.
Market pull
4/5
Pharma companies (Novartis, BMS) have a high urgency and established budget for companion diagnostics to reduce clinical trial failure rates in immuno-oncology.
Novelty & moat
3/5
While the specific target (IL-38) is novel, the mechanism (IHC-based patient stratification) is a known pattern seen in the Hsp70 and PD-L1 ideas in the catalog.
Feasibility
5/5
Developing a standardized IHC or RNA-ISH assay for a known protein is a routine laboratory procedure with a very short path to a demoable prototype.
Wedge clarity
5/5
The wedge is exceptionally sharp: a single test for a single protein to enroll patients in a specific set of clinical trials.
Simplicity / focus
5/5
The idea avoids 'platform' creep and focuses entirely on one diagnostic product with one clear utility.

Scored by Gemma 4 · 11 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Ventana Medical Systems (Roche)company

    Ventana is the leading developer of IHC-based companion diagnostics for oncology drugs; an IL-38 assay fits their established model of co-developing tissue tests with pharma partners.

  • Novartiscompany

    Novartis has a broad immuno-oncology pipeline and experience with IL-1 family targets (canakinumab); an IL-38 blocking program would need exactly this kind of patient-selection biomarker.

  • Bristol Myers Squibbcompany

    BMS's checkpoint inhibitor franchise is limited by non-responding 'cold' tumors; IL-38 blockade with a companion diagnostic could expand their addressable patient population.

  • Society for Immunotherapy of Cancerorganization

    SITC members include translational researchers who would adopt a standardized IL-38 scoring system to stratify patients in immuno-oncology studies.

Research it builds on

  1. IL-1 family cytokines in inflammation and immunity
    Cecília Garlanda, Irene Di Ceglie, Sébastien Jaillon · 2025 · 123 citations
    All ideas from this paper →
Leave feedback
feasibility